BHC - Embedded Expectations Analysis - 2018 08 20
Bausch Health Companies Inc. (BHC:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 12.0x Uniform P/E. At these levels, markets are pricing in bearish expectations for the firm, and while management may lack confidence in their ability to sustain current robust growth rates, long-term equity upside remains warranted should BHC simply maintain current profitability levelsSpecifically, management may be concerned about their ability to sustain current robust growth rates within their top ten products. Specifically, they may be concerned about B+L/International segment growth rates, particularly related to Global Vision Care. Additionally, they may lack confidence in their ability to maintain strong sales of their prescription and branded generic products, and high sales volume through Amazon. Finally, they may have concerns about the slow sales growth of their SILIQ product
However, management is confident in their goal to reduce leverage of the company, potentially through an equity raise, in order to free up capital for value accretive investments. Moreover, market expectations for Uniform ROA to decline to levels not seen since the Great Recession are far too bearish. As such, longer-term equity upside and multiple expansion are warranted.
Valeant Pharmaceuticals International is a pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). Co. has two operating and reportable segments: Developed Markets, which focuses in dermatology, neurology, gastrointestinal disorders, and eye health therapeutic; and Emerging Markets, which focuses primarily on branded generics, OTC products, and medical devices.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
- GAAP and IFRS have failed to provide rules for reliable financial statement reporting
- Stock analyst recommendations are not grounded in disciplined financial analysis
- Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
- Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
- Corporate credit ratings remain years behind the fundamental underpinnings of company performance
- Stock analysts continue to make recommendations with deeply inherent biases
- Research firms have failed to break down the walls between credit, equity, and macroeconomic research
- The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.